Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD in Fragile X Syndrome
NCT06261450Phase 2Not yet recruiting
- Sponsor
- Université de Sherbrooke
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in Fragile X syndrome (FXS) comparing CBD first with Placebo first (2 arms). Primary endpoint: Short Intracortical Inhibition. Planned start May 2025; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT06261450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06261450.